



Hiving off pharma R&D units - the key to lower risk and better valuation?

ValueNotes Database, March 26, 2008

URL: <http://www.pr9.net/business/services/7707march.html>

The Indian pharmaceutical industry is becoming competitive. In an attempt to reduce risk companies are planning strategies to hive off their R&D units. This is meant to focus on improved and innovative investment in R&D to achieve faster growth in the new chemical entity (NCE) business and value addition in the core generics business.

PR9.NET March 26, 2008 - Pune, India - As the industry becomes more and more competitive, Indian pharmaceutical companies are aggressively planning strategies to de-risk their business and are resorting to hiving off their R&D units. This is meant to reduce risk in the core generics business and to focus on improved and innovative investment in R&D, serving the dual purpose of achieving faster growth in the new chemical entity (NCE) business and value addition in the core generics business.

Dr. Reddy's Labs and Sun Pharma were the pioneers of this trend in the Indian market. Nicholas Piramal, Wockhardt and Ranbaxy are also planning similar moves in an attempt to reduce the risk in the parent company. The R&D firms can then focus on basic research and raise funds through PE funds, VCs or by way of an independent listing. This way, the interests of shareholders who may be risk-averse are protected, while options are provided to those with a larger risk appetite.

The fact that India has still not launched its first NCE has led many industry experts to be skeptical of the trend of hiving off R&D units. Some like Glenmark Pharma have hived off the generics business instead, and retained the R&D business, expecting better valuations for a generics business.

There are no clear-cut solutions, but Poonam Bhana, analyst at ValueNotes believes that hiving off R&D units is a judicious decision. It gives shareholders of the existing company an option to exit the risky R&D business while unlocking value of the R&D pipeline in the new company and also attracting investors that are prepared for a long wait before revenues flow in.

To minimize risk in the R&D companies, most firms are opting for collaborative R&D, for instance, Ranbaxy with GSK, Nicholas Piramal with Eli Lilly and Glenmark with Merck. Revenues in collaborative R&D business may flow in the form of royalty and/or milestone payments.

ValueNotes has published a report on Pharmaceutical Outsourcing in Drug Discovery and Development in April 2007. Subsequent updates have focused on key trends in the space such as partnerships and alliances, increasing role of bioinformatics in R&D, integrated offerings of vendors.

ValueNotes Database
301, Venus Point, 1226/1 Off F.C. Road, Pune – 411004, INDIA
Tel: +91 20 66010423/24
URL: www.sourcingnotes.com
Contact person: Arpita Bedekar
Email: bporesearch@valuenotes.biz

###

About ValueNotes Database

ValueNotes Database is a leading provider of business intelligence and research, with expertise across selected domains and types of customer needs. Working with clients across the globe we have significant understanding of international markets.

The ValueNotes Outsourcing Practice is one of the largest information providers on the outsourcing industry. Our Outsourcing Practice uses a comprehensive, analytical framework providing fresh insights into the fast emerging and yet, complex outsourcing space. We extensively track the outsourcing space in-depth through a regular analysis of news and events and continuous primary research and contact with the industry.

To learn more about the ValueNotes Outsourcing Practice, see samples, order reports, or provide us with your feedback on this research, please go to www.valuenotes.biz or write to bporesearch@valuenotes.biz. You can also call us at 91 20 6601 0423 / 6601 0424

Phone: 91 20 66010423
Website: <http://www.valuenotes.biz>
E-Mail: bporesearch@valuenotes.biz